Sarcoma UK is calling on the National Institute for Health and Care Excellence (NICE), NHS England, and pharmaceutical companies to have flexibility so that cancer patients in England with few treatment options can access the latest treatments as soon as possible. National bone and soft tissue cancer charity, Sarcoma UK, was disappointed to see that […]
Read More… from Calls For Flexibility To All ‘Game Changing’ Cancer Treatments
‘- Aggressive stomach and gullet cancers evolve escape routes under selective pressure from immune system – Findings underline importance of cancer evolution, and could help optimise immunotherapy Aggressive, highly mutated cancers evolve escape routes in response to immune attacks in an ‘evolutionary arms race’ between cancer and the immune system, a new study reports. Gullet […]
Read More… from Cancers Engaged in Evolutionary Arms Race with Immune System
· Only 28 per cent of people believe cancers can be controlled long term – yet the average patient now lives more than 10 years from diagnosis · Just 26 per cent of people think we are making major progress against cancer, even though average survival time from cancer has approximately doubled in a decade […]
Read More… from Cancer Research Offers More Hope Than People Think
Sarcoma UK is disappointed to see that life extending cancer drug trabectedin (Yondelis) will not be made available routinely on the NHS to sarcoma patients in Scotland. Trabectedin, a chemotherapy drug which has been routinely available in the rest of the UK for over a decade, has been denied approval for regular use in Scotland […]
Read More… from Life Extending Cancer Drug will not be made Available to all Patients in Scotland
Researchers at Queen’s University Belfast have received the first scientific research grant from MDS UK to improve treatment for Myelodysplastic Syndromes (MDS), a type of bone marrow cancer. Myelodysplastic Syndromes (MDS) are a form of bone marrow cancer whereby the bone marrow gradually fails to produce mature healthy cells. In some patients, MDS can progress […]
Immunotherapy pembrolizumab keeps some patients alive for three years or more Pembrolizumab either used alone or in combination with chemotherapy was more effective than a standard cocktail of chemotherapy drugs in a study involving nearly 900 patients. For patients who responded to treatment, the duration of response was five times longer for pembrolizumab alone than […]
Read More… from Immunotherapy Backed as Standard First-line Treatment for Head and Neck Cancer
It is a while since I have written a blog. My disease has been stable for just over a year now and I have focused on living life as normally as possible, contributing where I can through work, and making sure to do some fun things in the meantime. Highlights include being at Lords for […]
The inaugural London Global Cancer Week will launch at the Royal Society of Medicine on Monday 25 November. The week-long series of discussions and events will examine the impact of the rising global incidence of cancer, the challenges the cancer pandemic poses to the implementation of universal health coverage and the contribution of UK partners […]
A new type of drug that blocks one of cancer’s key evolutionary escape routes from chemotherapy could be used to treat aggressive breast cancers, a new study has shown. Scientists at The Institute of Cancer Research, London, found that the drug could reinvigorate the response to chemotherapy in cancers that had become resistant, in both […]
Read More… from New Evolution-busting Drug Overcomes Resistance in Aggressive Breast Cancers
· First clinical study to show link between types of gut bacteria and radiotherapy-induced gut damage · Studying patients’ bacterial fingerprint could help predict, prevent or treat gut damage following radiotherapy Taking a ‘fingerprint’ of the mix of bacteria in the gut can indicate how susceptible individual cancer patients are to gut damage as a […]
Read More… from Gut Bacteria “Fingerprint” Predicts Radiotherapy Side Effects